Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation

Influence of age, obesity, and hematocrit

Gary C Yee, Timothy R McGuire, Dennis J. Gmur, Thomas P. Lennon, H. Joachim Deeg

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Blood cyclosporine pharmacokinetics were studied in 85 patients aged 1-52 (median: 22) years undergoing allogeneic bone marrow transplantation for the treatment of hematologic disease. Pharmacokinetic studies were carried out during the first two weeks posttransplant after an intravenous dose of 2.1—4.4 mg/kg. Whole-blood cyclosporine concentrations were measured by high-performance liquid chromatography. Multiple stepwise regression analysis indicated that age (P<0.001) and hematocrit (P<0.05) correlated with cyclosporine clearance (CL) while steady-state volume of distribution (V„) did not correlate with any of the factors studied. Cyclosporine CL significantly differed among nonobese patients in different age groups; patients <10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or >40 years old (mean CL: 8.5—10.3 ml/min/kg) (P<0.05). No significant differences in cyclosporine CL and V„ were observed between obese (>125% ideal body weight) patients and age-matched nonobese patients. Hematocrit values (range: 24—39) were inversely correlated with cyclosporine CL, which suggests that red blood cells function as important ligands in cyclosporine binding. These results show that blood cyclosporine CL is higher in marrow transplant recipients than in solid organ transplant recipients and that these differences may be related to lower hematocrits in marrow transplant recipients compared with solid organ transplant recipients. When compared with previously published serum cyclosporine CL data, our findings suggest that age-related changes in CL are primarily related to changes in plasma protein binding and that obesity does not significantly alter cyclosporine CL and Vss.

Original languageEnglish (US)
Pages (from-to)399-402
Number of pages4
JournalTransplantation
Volume46
Issue number3
StatePublished - Jan 1 1988

Fingerprint

Hematocrit
Cyclosporine
Pharmacokinetics
Obesity
Transplantation
Bone Marrow
Transplants
Ideal Body Weight
Hematologic Diseases
Homologous Transplantation
Bone Marrow Transplantation
Protein Binding
Blood Proteins
Erythrocytes
High Pressure Liquid Chromatography
Regression Analysis
Ligands
Transplant Recipients
Serum

ASJC Scopus subject areas

  • Transplantation

Cite this

Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation : Influence of age, obesity, and hematocrit. / Yee, Gary C; McGuire, Timothy R; Gmur, Dennis J.; Lennon, Thomas P.; Deeg, H. Joachim.

In: Transplantation, Vol. 46, No. 3, 01.01.1988, p. 399-402.

Research output: Contribution to journalArticle

@article{84db1414686942e4a52c1782d743d1f2,
title = "Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: Influence of age, obesity, and hematocrit",
abstract = "Blood cyclosporine pharmacokinetics were studied in 85 patients aged 1-52 (median: 22) years undergoing allogeneic bone marrow transplantation for the treatment of hematologic disease. Pharmacokinetic studies were carried out during the first two weeks posttransplant after an intravenous dose of 2.1—4.4 mg/kg. Whole-blood cyclosporine concentrations were measured by high-performance liquid chromatography. Multiple stepwise regression analysis indicated that age (P<0.001) and hematocrit (P<0.05) correlated with cyclosporine clearance (CL) while steady-state volume of distribution (V„) did not correlate with any of the factors studied. Cyclosporine CL significantly differed among nonobese patients in different age groups; patients <10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or >40 years old (mean CL: 8.5—10.3 ml/min/kg) (P<0.05). No significant differences in cyclosporine CL and V„ were observed between obese (>125{\%} ideal body weight) patients and age-matched nonobese patients. Hematocrit values (range: 24—39) were inversely correlated with cyclosporine CL, which suggests that red blood cells function as important ligands in cyclosporine binding. These results show that blood cyclosporine CL is higher in marrow transplant recipients than in solid organ transplant recipients and that these differences may be related to lower hematocrits in marrow transplant recipients compared with solid organ transplant recipients. When compared with previously published serum cyclosporine CL data, our findings suggest that age-related changes in CL are primarily related to changes in plasma protein binding and that obesity does not significantly alter cyclosporine CL and Vss.",
author = "Yee, {Gary C} and McGuire, {Timothy R} and Gmur, {Dennis J.} and Lennon, {Thomas P.} and Deeg, {H. Joachim}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "46",
pages = "399--402",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation

T2 - Influence of age, obesity, and hematocrit

AU - Yee, Gary C

AU - McGuire, Timothy R

AU - Gmur, Dennis J.

AU - Lennon, Thomas P.

AU - Deeg, H. Joachim

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Blood cyclosporine pharmacokinetics were studied in 85 patients aged 1-52 (median: 22) years undergoing allogeneic bone marrow transplantation for the treatment of hematologic disease. Pharmacokinetic studies were carried out during the first two weeks posttransplant after an intravenous dose of 2.1—4.4 mg/kg. Whole-blood cyclosporine concentrations were measured by high-performance liquid chromatography. Multiple stepwise regression analysis indicated that age (P<0.001) and hematocrit (P<0.05) correlated with cyclosporine clearance (CL) while steady-state volume of distribution (V„) did not correlate with any of the factors studied. Cyclosporine CL significantly differed among nonobese patients in different age groups; patients <10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or >40 years old (mean CL: 8.5—10.3 ml/min/kg) (P<0.05). No significant differences in cyclosporine CL and V„ were observed between obese (>125% ideal body weight) patients and age-matched nonobese patients. Hematocrit values (range: 24—39) were inversely correlated with cyclosporine CL, which suggests that red blood cells function as important ligands in cyclosporine binding. These results show that blood cyclosporine CL is higher in marrow transplant recipients than in solid organ transplant recipients and that these differences may be related to lower hematocrits in marrow transplant recipients compared with solid organ transplant recipients. When compared with previously published serum cyclosporine CL data, our findings suggest that age-related changes in CL are primarily related to changes in plasma protein binding and that obesity does not significantly alter cyclosporine CL and Vss.

AB - Blood cyclosporine pharmacokinetics were studied in 85 patients aged 1-52 (median: 22) years undergoing allogeneic bone marrow transplantation for the treatment of hematologic disease. Pharmacokinetic studies were carried out during the first two weeks posttransplant after an intravenous dose of 2.1—4.4 mg/kg. Whole-blood cyclosporine concentrations were measured by high-performance liquid chromatography. Multiple stepwise regression analysis indicated that age (P<0.001) and hematocrit (P<0.05) correlated with cyclosporine clearance (CL) while steady-state volume of distribution (V„) did not correlate with any of the factors studied. Cyclosporine CL significantly differed among nonobese patients in different age groups; patients <10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or >40 years old (mean CL: 8.5—10.3 ml/min/kg) (P<0.05). No significant differences in cyclosporine CL and V„ were observed between obese (>125% ideal body weight) patients and age-matched nonobese patients. Hematocrit values (range: 24—39) were inversely correlated with cyclosporine CL, which suggests that red blood cells function as important ligands in cyclosporine binding. These results show that blood cyclosporine CL is higher in marrow transplant recipients than in solid organ transplant recipients and that these differences may be related to lower hematocrits in marrow transplant recipients compared with solid organ transplant recipients. When compared with previously published serum cyclosporine CL data, our findings suggest that age-related changes in CL are primarily related to changes in plasma protein binding and that obesity does not significantly alter cyclosporine CL and Vss.

UR - http://www.scopus.com/inward/record.url?scp=0023695932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023695932&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 399

EP - 402

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -